Science corp. names Nevada Sanchez as Executive Vice President of Engineering. ALAMEDA, Calif.-(BUSINESS WIRE)-Science Corporation, the full-stack neural engineering and brain-computer interface (BCI) company focused on restoring and extending life, today announced the appointment of Nevada Sanchez as Executive Vice President of Engineering. Sanchez will provide engineering leadership across the organization and will report directly to Science CEO and co-founder Max Hodak. Sanchez co-founded Butterfly Network, Inc. (NYSE: BFLY) in 2011, and until recently served as Senior Vice President and Chief Innovation Officer. While there, he conceived and led the development of the world's first ultrasound system on a chip, building the engineering organization that took the technology from a prototype to a globally deployed platform. His work helped establish Butterfly as a pioneer in semiconductor-based medical imaging. The appointment comes after Science's successful $230 million Series C capital raise, and as it begins the European commercial launch of PRIMA, its BCI retinal implant. Science is also accelerating development of its Biohybrid neural interface and Vessel perfusion programs, and expanding the Science Foundry, with its comprehensive MEMS fabrication capabilities. "We are dedicated to solving some of medicine's hardest problems through neural engineering. This requires constant innovation at scale and the best minds working together," said Hodak. "Nevada has spent the past fifteen years creating an entirely new sensing technology at Butterfly and scaling it to a product used by clinicians globally to reveal what was previously invisible. We are thrilled he's joining us." "Science is working on some of the most interesting and consequential engineering problems in medicine: restoring vision with retinal implants, building the next generation of implantable neural interfaces, and developing technologies for long-term organ support," said Sanchez. "I have tremendous respect for what Max and the Science team have already accomplished, and I look forward to what we can accomplish together, which will change lives around the world." Sanchez holds an S.B. in Electrical Engineering and Computer Science, an S.B. in Mathematics with a minor in Physics, and an M.Eng. in Electrical Engineering and Computer Science from MIT. He received the Henry Ford II Scholar Award, given to the top student in the MIT School of Engineering, and was named a Hertz Fellow before leaving academia to co-found Butterfly Network. Science's PRIMA retinal implant is the only treatment to have successfully restored form vision to clinical trial patients blinded by late-stage macular degeneration. The PRIMA clinical trial results were featured in The New England Journal of Medicine and on the cover of Time. PRIMA has received a CE (Conformité Européenne) mark under the European Union Medical Device Regulation from DEKRA, authorizing its commercial availability across 30 European countries. An FDA process is also underway. About Science Corporation Science Corporation is a vertically-integrated, full-stack neural engineering company. Our mission is to restore and extend life by transcending the limits of biology. We are developing advanced brain-computer interface technologies and devices to address critical unmet medical needs and, longer term, to transform the human condition through neural engineering and advanced perfusion technology. Science is headquartered in Alameda, Calif. For more information please visit: www.science.xyz.

Science welcomes Nevada Sanchez as Executive Vice President of Engineering. As Science continue to make progress on its key goals, I'm excited to announce the appointment of Nevada Sanchez as Executive Vice President of Engineering. Nevada will provide leadership across the Science engineering organizations and will report directly to me. Nevada co-founded Butterfly Network, Inc. in 2011, and until recently served as Senior Vice President and Chief Innovation Officer. While there, he conceived and led the development of the world's first ultrasound system on a chip, building the engineering organization that took the technology from a prototype to a globally deployed platform. His work helped establish Butterfly as a pioneer in semiconductor-based medical imaging. Nevada holds an S.B. in Electrical Engineering and Computer Science, an S.B. in Mathematics with a minor in Physics, and an M.Eng. in Electrical Engineering and Computer Science from MIT. Earlier this year Science raised a $230 million Series C, and Nevada joins Science at a time of significant growth and transition in the company's life and as Science begin the European commercial launch of PRIMA, its BCI retinal implant. Science is also accelerating development of its Biohybrid neural interface and Vessel perfusion programs, and expanding the Science Foundry, with its comprehensive MEMS fabrication capabilities. Its team is dedicated to solving some of medicine's hardest problems through neural engineering. This requires constant innovation at scale and the best minds working together. Nevada has spent the past fifteen years creating an entirely new sensing technology at Butterfly and scaling it to a product used by clinicians globally to reveal what was previously invisible. Nevada brings exactly the kind of cross-disciplinary engineering leadership required to turn ambitious scientific ideas into products that work reliably in the real world. I'm excited to welcome him to Science and to see the impact he will have on its team, its technology, and ultimately the patients Science serve. * Max Hodak, CEO Published. July 29, 2026

The eye chip financing brain-computer interfaces gets EU green light with PRIMA vision restoration. Science Corporation's PRIMA vision restoration device has received CE marking from European regulators, clearing it for commercial sale across 30 European countries, and giving the Neuralink co-founder behind the company his first real revenue engine for far more ambitious plans. The certification, granted by the notified body Science Corporation, came under the EU Medical Device Regulation. Science Corp. describes PRIMA as the first brain-computer interface device to receive CE marking specifically for form vision restoration: the ability to read letters, numbers, and words. The US Food and Drug Administration has also handed the device a designation that opens the door to expedited review, potentially extending PRIMA's reach to two rare forms of blindness beyond age-related macular degeneration (AMD). The case for PRIMA vision restoration. AMD destroys the light-sensitive cells at the back of the eye, robbing patients of central vision and making it hard to read or recognise faces. Research published via PubMed Central describes geographic atrophy (the advanced dry form of AMD) as the leading cause of irreversible blindness, affecting over 5 million people globally. The PRIMA implant itself is almost absurdly small: Retinal Physician reports the device measures 2mm x 2mm x 30μm and contains 378 individual photovoltaic cells, each 100μm across, sensitive to near-infrared light. During an hour-long outpatient procedure, surgeons place the chip beneath the retina. Patients then wear camera-equipped glasses that capture the world, process it, and project it onto the implant, which stimulates the overlying bipolar cells. The clinical evidence behind it is harder to dismiss than the typical pre-launch slide deck. The PRIMAvera trial (NCT04676854), an open-label, prospective, single-group study enrolling 38 patients, found that 81% of participants achieved clinically meaningful visual improvement at 12 months, with a mean improvement of 0.51 logMAR (equivalent to 25.5 letters on a standard eye chart), according to results published in the New England Journal of Medicine on 15 January 2026. Thirty-two of the 38 patients completed the full 12-month study. Retinal Physician puts the maximum improvement seen at 1.18 logMAR, a figure that would represent a dramatic shift in functional sight. A separate report from Chosun put the proportion of patients who regained reading ability at 84%, though that figure may reflect a different measured outcome from the 81% clinically meaningful improvement threshold reported by Retinal Physician; Retinal Physician's specialty-trade analysis is the figure used here. Frank Holz, MD, Chair of the Department of Ophthalmology at the University Hospital of Bonn, served as lead investigator and lead author on the NEJM paper, according to the Science Corp. European commercial launch announcement. CEO Max Hodak is not short of anecdotes to humanise the numbers. 'One of our patients in France finished a 300-page novel a little while ago, and sent us the book,' he told TechCrunch. 'We have a sketch on the wall [that] one of our patients drew of the Sydney Opera House. There are videos of patients playing crossword puzzles and filling in Sudoku.' Stanford roots, parisian courts, and a german launch. The technology Science Corp. is now commercialising did not originate inside the company. PRIMA was originally developed at Stanford University, and its commercial rights passed through Pixium Vision, a French firm. When Pixium went into liquidation, Science Corp. acquired the intellectual property through a proceeding in the Paris Commercial Court in 2024, according to MassDevice. The April 2024 acquisition announcement confirmed Hodak's acknowledgement of the Stanford origins at the time. Science Corp. used its internal platform to build out the documentation and evolve the product toward regulatory approval. Germany, where the clinical trials were held, is the first target market; the company expects the first commercial procedure there as early as September. Pricing will land in the hundreds of thousands of dollars per device, with reimbursement discussions under way with European healthcare providers. Hodak is candid about why all of this matters beyond ophthalmology. 'The thing that the space needs is a company making $100 million a year of revenue,' he said. 'There's this risk that the whole thing enters a winter, and so Hesper Herald think it's important to build a sustainable business as Hesper Herald develop these longer-term technologies.' Those longer-term technologies include a bio-hybrid brain sensor, developed in collaboration with Dr Murat Günel, Chair of Yale Medical School's Department of Neurosurgery, targeted at direct neural implantation. The glasses that drive PRIMA currently require a battery pack to operate. Science Corp. is working on a next-generation chip and a sleeker form factor, with something approximating Meta's AR glasses cited as the aspiration. Whether the reimbursement conversations move fast enough for PRIMA to generate that $100m anchor before the longer-term BCI research needs more runway is the question investors will be watching this autumn. Marcus Hale has been filing general news for the better part of fifteen years. He started at a regional evening paper, moved to a mid-sized digital outlet covering UK news, and spent three years as a general assignment reporter before going freelance. He has covered inquests, council elections, infrastructure announcements, and the kind of stories that sit on page five but matter on page one. He writes about public services, housing, local government, and the institutional stories that take six months to develop and thirty seconds to read. He prefers facts to angles and considers that unfashionable. Marcus lives in Bristol. He still reads the local paper and thinks that makes him an endangered species. July 26, 2026 July 25, 2026